| アブストラクト | Excessive carbapenem use has contributed to the spread of carbapenem-resistant bacteria. In response, Japan's revised National Action Plan on Antimicrobial Resistance (AMR) 2023-2027 set the goal of a 20 % reduction in carbapenem use. The aim of this study is to reveal the circumstances associated with carbapenem use in diagnosis procedure combination (DPC) community hospitals and fee-for-service hospitals, which account for the majority of the hospitals in Japan. We analyzed publicly available data from the Survey of Discharged Patients conducted by the Ministry of Health, Labour and Welfare in 2020. We used multiple regression analysis to identify the factors associated with carbapenem use in small- to medium-sized hospitals. Considerable carbapenem use was observed in small- to medium-sized hospitals. There was a large difference in carbapenem use among curative care beds in both DPC community hospitals and non-DPC hospitals. Linear regression models showed the significant association of several major diagnostic categories (MDCs) with carbapenem use. In particular, rates of MDC No.02 (eye) and 05 (circulatory system) were potentially associated with excessive or inappropriate carbapenem use. A notable and novel study finding was that there was a large difference in carbapenem consumption as the number of curative care beds increased in both DPC community hospitals and non-DPC hospitals. This may contribute to the identification of carbapenem overuse and toward achieving the goal of the National Action Plan on AMR 2023-2027. Furthermore, identifying factors associated with carbapenem use helps in understanding disease-specific prescribing practices and detecting potential overuse. |
|---|
| ジャーナル名 | Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy |
|---|
| 投稿日 | 2023/11/13 |
|---|
| 投稿者 | Yamaguchi, Kozue; Maeda, Masayuki; Ohmagari, Norio; Muraki, Yuichi |
|---|
| 組織名 | Division of Infection Control Sciences, Department of Clinical Pharmacy, School;of Pharmacy, Showa University, Tokyo, 142-8555, Japan. Electronic address:;kozue.y@pharm.showa-u.ac.jp.;m-maeda@pharm.showa-u.ac.jp.;AMR Clinical Reference Center, Disease Control and Prevention Center, National;Center for Global Health and Medicine, Tokyo, 162-8655, Japan. Electronic;address: nohmagari@hosp.ncgm.go.jp.;Department of Clinical Pharmacoepidemiology, Kyoto Pharmaceutical University,;Kyoto, 607-8414, Japan. Electronic address: y-muraki@mb.kyoto-phu.ac.jp. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/37952842/ |
|---|
